Table 1.
Baseline and disease characteristics for patients participating in the multiple-cycle extension
| Characteristic | NEPA + DEX (N = 635) | Oral PALO + DEX (N = 651) |
|---|---|---|
| Gender (%) | ||
| Female | 98.3 | 98.0 |
| Male | 1.7 | 2.0 |
| Median age (years) | 54.0 | 54.0 |
| Ethnic group (%) | ||
| White | 77.3 | 79.0 |
| Asian | 15.6 | 15.2 |
| Hispanic | 6.6 | 5.4 |
| Black | 0.2 | 0.2 |
| Other | 0.3 | 0.3 |
| Cancer type (%) | ||
| Breast | 97.8 | 97.7 |
| Other | 2.2 | 2.3 |
| ECOG performance status (%) | ||
| 0 | 68.7 | 68.5 |
| 1 | 30.7 | 31.3 |
| 2 | 0.6 | 0.2 |
| Alcohol consumption (%) | ||
| No | 80.9 | 81.3 |
| Occasionally | 18.7 | 18.1 |
| Regularly | 0.3 | 0.6 |
| Chemotherapy (%) | ||
| Cyclophosphamide | 99.8 | 100 |
| Doxorubicin | 67.2 | 63.0 |
| Epirubicin | 32.8 | 37.0 |
| Mean total dose (mg) | ||
| Cyclophosphamide | 987.7 | 986.4 |
| Doxorubicin | 97.7 | 98.3 |
| Epirubicin | 131.2 | 131.1 |
NEPA netupitant/palonosetron, PALO palonosetron, DEX dexamethasone, ECOG Eastern Cooperative Oncology Group